New York City-based Weill Cornell and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center will add Aclarion’s Nociscan tool, according to an April 8 news release.
Weill Cornell and Aclarion established a commercial agreement, and Nociscan will be used as part of the trial “A Prospective Review of Bone Marrow Aspirate Stem Cell Concentrate (BMAC) for Osteoarthritis and Degenerative Disc Disease.”
The study will investigate whether the dose and quantity of bone marrow aspirate stem cell concentrate for osteoarthritis and degenerative disc disease in the spine. Some patients in the study will be eligible for Nociscan, an AI tool to help physicians identify the source of chronic low back pain.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.